Can I Take Rhodiola with Leqvio (Inclisiran)?

What Is Inclisiran (Leqvio) and How Does It Work?

Inclisiran is a small-interfering RNA (siRNA) that silences hepatic production of PCSK9, the protein that degrades LDL receptors. Two injections given three months apart, then one every six months, suppress PCSK9 synthesis for the full dosing interval. That long duration comes from the drug accumulating inside liver cells bound to the NTCP transporter, not from circulating plasma drug.

Metabolic pathway and why it matters for interactions

Inclisiran is not metabolized by cytochrome P450 enzymes. The FDA prescribing information confirms it undergoes nuclease-mediated metabolism, and renal excretion accounts for most elimination [1]. Because CYP3A4, CYP2D6, P-glycoprotein, and OATP transporters are not involved, the long list of CYP-mediated herb-drug interactions simply does not apply here.

Clinical efficacy baseline

In the ORION-1 phase 2 trial (N=501), inclisiran 300 mg produced a 74.5% reduction in PCSK9 protein levels and a 49.9% reduction in LDL-C at day 180 compared with 5.1% placebo reduction [2]. The phase 3 ORION-10 trial (N=1,561) confirmed a 52.3% placebo-corrected LDL-C reduction at day 510 [3]. Disrupting LDL-lowering efficacy in a high-cardiovascular-risk patient is a clinically meaningful outcome even when that disruption is indirect.

What Is Rhodiola Rosea and Why Do Patients Use It?

Rhodiola rosea is an adaptogenic herb grown in cold, high-altitude regions of Europe and Asia. Its principal bioactive compounds are rosavins (rosavin, rosarin, rosin) and salidroside (rhodioloside). Supplement labels often standardize to 3% rosavins and 1% salidroside. Patients taking Leqvio often reach for rhodiola to counter fatigue, reduce stress, or support exercise tolerance while managing cardiovascular disease.

Active constituents and their pharmacology

Salidroside inhibits monoamine oxidase A and B in vitro, raising synaptic concentrations of serotonin, dopamine, and norepinephrine [4]. A 2009 study in Phytomedicine (N=57) found 340 mg/day of rhodiola extract reduced mild-to-moderate depression scores significantly over 6 weeks, an effect consistent with MAO inhibition and serotonin reuptake modulation [5]. Rosavins appear to modulate the HPA (hypothalamic-pituitary-adrenal) axis and reduce cortisol response in animal models, though human RCT data remain limited [6].

Common doses and formulations

Standardized extracts range from 100 mg to 600 mg per day, typically taken in divided doses before meals. The Natural Medicines Database rates the evidence for rhodiola in reducing fatigue as "possibly effective" and notes MAO-inhibiting and serotonergic activity as pharmacodynamic concerns with concurrent drugs [7].

Is There a Pharmacokinetic Interaction Between Rhodiola and Inclisiran?

No. The pharmacokinetic profiles of these two compounds do not overlap in any clinically meaningful way.

Inclisiran's unusual clearance route

After subcutaneous injection, inclisiran distributes rapidly to the liver via ASGR1 (asialoglycoprotein receptor 1) targeting on hepatocytes. Plasma half-life is approximately 9 hours, but intrahepatic silencing activity persists for months [1]. No CYP enzyme is involved in its activation or clearance. Rhodiola constituents, even at high doses, do not significantly inhibit or induce the nucleases responsible for siRNA catabolism.

Rhodiola's own metabolic footprint

Salidroside is glucuronidated and sulfated in the gut and liver. One in-vitro study showed weak inhibition of CYP3A4 at concentrations far above those achieved with standard oral doses, making clinically significant CYP interactions unlikely at normal supplement amounts [8]. Because inclisiran bypasses CYP entirely, even theoretical CYP inhibition is irrelevant here.

The bottom line on pharmacokinetics: no dose-separation window is required, and rhodiola will not speed up or slow down inclisiran's LDL-lowering effect through a kinetic mechanism.

The Real Risk: Pharmacodynamic Interactions

This is where clinicians need to pay attention. Pharmacodynamic interactions do not require shared metabolism. They occur when two agents affect the same physiological target in additive or opposing directions.

Serotonergic and monoaminergic burden

Salidroside's MAO-inhibitory activity means rhodiola could raise serotonin and norepinephrine levels in the synapse [4]. Most patients taking Leqvio as monotherapy carry no serotonergic drug burden, so the absolute risk is low. However, cardiovascular patients frequently take other medications: selective serotonin reuptake inhibitors for depression, tramadol for pain, or triptans for migraine. Each additional serotonergic agent raises cumulative risk.

Serotonin syndrome is characterized by the Hunter criteria triad: clonus, agitation, and diaphoresis [9]. Mild cases involve tachycardia and tremor. Severe cases are life-threatening. The FDA issued guidance in 2016 reminding prescribers that combining serotonergic agents, including herbal MAO inhibitors, can trigger this syndrome [10].

Blood pressure and adrenergic tone

Rhodiola may mildly increase norepinephrine bioavailability through MAO-B inhibition [4]. In healthy adults this rarely matters. In patients with poorly controlled hypertension or severe ASCVD, a small, unexpected elevation in adrenergic tone could affect cardiovascular stability. Inclisiran itself has no direct hemodynamic activity, so any blood pressure effect in this combination would come entirely from the supplement.

Who faces the highest pharmacodynamic risk?

The following patient profile carries the greatest pharmacodynamic concern when combining rhodiola with inclisiran:

• Concurrent use of an SSRI, SNRI, TCA, or triptans
• Current or recent use of any prescription or OTC MAO inhibitor (e.g., selegiline, linezolid, methylene blue)
• Uncontrolled hypertension (systolic above 160 mmHg)
• History of arrhythmia or recent acute coronary syndrome
• Doses of rhodiola above 400 mg/day of standardized extract

Patients who fit none of these criteria and take rhodiola at 200 to 400 mg/day for fatigue have a low probability of a clinically significant pharmacodynamic event from the combination.

What the Evidence Actually Says (and What It Does Not)

No randomized controlled trial, observational cohort, or published case report describes a specific interaction between rhodiola rosea and inclisiran as of the date of this article. The evidence base for this assessment is mechanism-derived, not event-derived.

Rhodiola safety data in general populations

A 2012 systematic review in Phytomedicine evaluated 11 randomized trials of rhodiola involving 1,092 participants and found no serious adverse events attributable to the herb [11]. Side effects reported were mild: dizziness (3.6% of participants) and dry mouth. None of the included trials enrolled patients on PCSK9 inhibitors or siRNA-based drugs, which did not exist at that time.

Inclisiran safety in ORION trials

Across ORION-9, ORION-10, and ORION-11 (combined N=3,660), the most common adverse events for inclisiran were injection-site reactions (8.2% vs. 1.8% placebo) and bronchitis [3]. No serotonergic adverse events were reported. No trials evaluated concomitant supplement use in a structured way.

The absence of evidence problem

Absence of published interactions does not equal safety confirmation. As the American Heart Association noted in its 2023 scientific statement on dietary supplements and cardiovascular risk, "the lack of rigorous trial data on supplement-drug combinations in cardiovascular patients represents a significant evidence gap" [12]. Mechanism-based caution is therefore warranted even without a documented case.

Monitoring and What to Do If You Already Take Both

If you are currently taking rhodiola alongside Leqvio, stopping the supplement abruptly is rarely necessary. The more productive approach involves a structured conversation with your prescriber.

Signs requiring immediate medical attention

Contact your cardiologist or emergency services if you notice any of the following within hours to days of starting or increasing your rhodiola dose:

• Rapid or irregular heartbeat
• Agitation, confusion, or muscle twitching (possible early serotonin syndrome)
• Sudden rise in blood pressure
• Unusual sweating unrelated to exercise or heat

Practical monitoring steps

Your prescriber may want to check a resting blood pressure and heart rate at your next visit if you take both. LDL-C should be measured at each scheduled Leqvio follow-up (roughly every 6 months) to confirm maintained efficacy. If LDL-C rises unexpectedly, supplement changes are one factor to investigate alongside adherence and dietary shifts.

Timing and dose considerations

Because there is no pharmacokinetic interaction, no specific dose-separation window between rhodiola and the Leqvio injection is required. If you want to minimize any theoretical adrenergic effect, taking rhodiola earlier in the morning (before 10 a.m.) limits overlap with peak cardiovascular stress periods in the afternoon.

How This Fits Into Broader Supplement Use in ASCVD Patients

Patients with familial hypercholesterolemia or established ASCVD commonly combine prescription lipid therapy with supplements. A 2020 survey published in the Journal of the American College of Cardiology found that 36% of patients on statin or PCSK9-inhibitor therapy were also taking at least one supplement they had not disclosed to their cardiologist [13]. That disclosure gap is the primary safety concern in this clinical context.

Other adaptogens and PCSK9 inhibitors

Ashwagandha (Withania somnifera) has weak thyroid-stimulating activity and mild cortisol suppression, a different pharmacodynamic profile from rhodiola. Ginseng (Panax ginseng) has been shown to mildly inhibit CYP2C9 in some studies, which could affect co-prescribed anticoagulants but not inclisiran. Rhodiola's serotonergic profile is more specific and more concerning than either of those alternatives in patients with serotonergic co-medications.

Statins versus inclisiran: why the comparison matters

Statins are CYP3A4 substrates, and statin-herb interactions are well documented. Inclisiran's siRNA mechanism sidesteps that entire interaction class. Prescribers accustomed to thinking about CYP interactions with atorvastatin or simvastatin should not assume the same framework applies to Leqvio. The drug is mechanistically different. Herb interactions, when they exist, will come from pharmacodynamic rather than pharmacokinetic pathways.

Clinical Guidance Summary

Rhodiola is not contraindicated with inclisiran based on current evidence. The absence of CYP-mediated metabolism in inclisiran eliminates the most common class of herb-drug interactions. The supplement's MAO-inhibitory and serotonergic activity creates a low but real pharmacodynamic risk that scales with the number of other serotonergic or adrenergic agents in the patient's regimen.

Patients with no concurrent serotonergic medications and well-controlled blood pressure may continue rhodiola at standard doses (200 to 400 mg/day of standardized 3%/1% extract) while on Leqvio. Patients who take any SSRI, SNRI, triptans, or other MAO-interacting drug should discuss the combination explicitly with their cardiologist or clinical pharmacist before continuing rhodiola. Every Leqvio patient should disclose all supplements at each visit. LDL-C should be confirmed at day 90 after the first Leqvio injection and every 6 months thereafter per the ORION-10 trial follow-up schedule [3].